Free tool
FAERS Monitor: Restasis Multidose
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050790 or its brand name (Restasis Multidose, Cyclosporine). Reports on generic versions are filed under their own applications.
Reports
91,100
Serious
60,662
67% of reports
Hospitalization
20,597
Death reported
11,654
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective11,507
- off label use9,378
- eye irritation6,681
- product use in unapproved indication3,873
- eye pain3,413
- nausea3,174
- headache3,156
- diarrhoea3,140
- pyrexia3,112
- fatigue3,078
- vision blurred2,697
- pain2,657
- condition aggravated2,656
- pneumonia2,458
- pruritus2,331
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 908 |
| 2005 | 937 |
| 2006 | 1,072 |
| 2007 | 1,048 |
| 2008 | 1,793 |
| 2009 | 2,070 |
| 2010 | 2,639 |
| 2011 | 3,374 |
| 2012 | 2,715 |
| 2013 | 1,991 |
| 2014 | 2,616 |
| 2015 | 3,248 |
| 2016 | 4,300 |
| 2017 | 4,465 |
| 2018 | 4,346 |
| 2019 | 5,384 |
| 2020 | 5,813 |
| 2021 | 5,698 |
| 2022 | 7,320 |
| 2023 | 7,509 |
| 2024 | 8,330 |
| 2025 | 7,700 |
| 2026 | 5,818 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,963,059 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye irritationSignal | 6,681 | 30.2 | 29.4 | 167,084 |
| eye painSignal | 3,413 | 14.8 | 14.3 | 41,362 |
| vision blurredSignal | 2,697 | 4.6 | 4.4 | 7,509 |
| product use in unapproved indicationSignal | 3,873 | 3.6 | 3.5 | 7,417 |
| off label useSignal | 9,378 | 2.5 | 2.4 | 8,619 |
| pyrexiaSignal | 3,112 | 2.1 | 2.0 | 1,772 |
| condition aggravatedSignal | 2,656 | 2.0 | 2.0 | 1,387 |
| drug ineffectiveSignal | 11,507 | 2.0 | 2.0 | 6,310 |
| pneumonia | 2,458 | 1.8 | 1.7 | 810 |
| pruritus | 2,331 | 1.4 | 1.3 | 273 |
| headache | 3,156 | 1.2 | 1.1 | 74 |
| diarrhoea | 3,140 | 1.1 | 1.1 | 44 |
| pain | 2,657 | 1.0 | 1.0 | 0 |
| nausea | 3,174 | 0.9 | 0.9 | 20 |
| fatigue | 3,078 | 0.9 | 0.9 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.